Table 2.
Case | Age at diagnosis | Gender | Onset time (mo) | Type of IgG deposits | C1q deposition | Native kidney disease | Pattern of glomerular injury | Monoclonal gammopathy | Ref. |
1 | 24 | M | 43 | IgG3κ | N/A | T1DM | MPGN | None | Albawardi et al[64] (2011) |
2 | 68 | F | 156 | IgG1κ | N/A | PKD | MPGN | None | Albawardi et al[64] (2011) |
3 | 38 | F | 72 | IgG3κ | 1+ | T1DM | MesGN or EC | N/A | Hussain et al[72] (2017) |
4 | 61 | F | 98 | IgG3κ | C1q | MPGN | EC | None | Al-Rabadi et al[73] (2015) |
5 | 40 | F | 132 | IgG3κ | N/A | MPGN | MPGN | None | Al-Rabadi et al[73] (2015) |
6 | 46 | M | 49 | IgG1κ | 1+ | FSGS | MesGN | N/A | Li et al[77] (2017) |
7 | 69 | M | 6 | IgG3κ | 1+ | Obesity (FSGS?) | MPGN | N/A | Merhi et al[75] (2017) |
EPGN: Endocapillary proliferative glomerulonephritis; FSGS: Focal segmental glomerulosclerosis; MesGN: Mesangioproliferaitve glomerulonephritis; MPGN: Membranoproliferative glomerulonephritis; N/A: Not available; PGNMID: Proliferative glomerulonephritis with monoclonal IgG deposits; PKD: Polycystic kidney disease; T1DM: Type 1 diabetes mellitus; EC: Endocapillary proliferative; M: Male; F: Female.